Increase in white blood cell count and serum sodium level following the addition of lithium to carbamazephine treatment among three chronically psychotic male patients with disturbed affective states

Vieweg, W. Victor R.; Yank, G. R.; Rowe, W. T.; Hovermale, L. S.; Clayton, Anita H.

doi:10.1007/bf01064735

Cited by 11 publications

(4 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…45 Our study consistently demonstrated that lithium suppressed cell growth, induced apoptosis, and slightly potentiated the proapoptotic effect of cisplatin in colon cancer cells, inferring that lithium may actually favor the efficacy of cisplatin-based chemotherapy for certain types of cancers such as colon cancer. Moreover, in patients subjected to systemic chemotherapy for malignant tumors, lithium carbonate has been safely used to accelerate hematopoietic recovery and shorten the period of leukopenia, 12,47,48 again suggesting the safety of lithium therapy in chemotherapy patients.…”

Section: Discussionmentioning

confidence: 99%

“…11 Lithium has been well known to have a potent promotional effect on tissue repair and regeneration after injury in multiple organ systems, including the central nervous system and hematopoietic system, [12][13][14][15] whereas the effect of lithium on kidney repair and renal recovery after AKI is unknown. This study examined the effect of delayed administration of a single low dose of lithium on a murine model of cisplatin or ischemia/reperfusion-induced AKI.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Delayed Administration of a Single Dose of Lithium Promotes Recovery from AKI

Bao

Wang

et al. 2014

Journal of the American Society of Nephrology

View full text Add to dashboard Cite

Evidence suggests that glycogen synthase kinase 3b (GSK3b) contributes to AKI; however, its role in post-AKI kidney repair remains uncertain. Here, delayed treatment with a single dose of lithium, a selective inhibitor of GSK3b and a US Food and Drug Administration-approved mood stabilizer, accelerated recovery of renal function, promoted repopulation of renal tubular epithelia, and improved kidney repair in murine models of cisplatin-and ischemia/reperfusion-induced AKI. These effects associated with reduced GSK3b activity and elevated expression of proproliferative molecules, including cyclin D1, c-Myc, and hypoxia-inducible factor 1a (HIF-1a), in renal tubular epithelia. In cultured renal tubular cells, cisplatin exposure led to transient repression of GSK3b activity followed by a prolonged upregulation of activity. Rescue treatment with lithium inhibited GSK3b activity, enhanced nuclear expression of cyclin D1, c-Myc, and HIF-1a, and boosted cellular proliferation. Similarly, ectopic expression of a kinase-dead mutant of GSK3b enhanced the expression of cyclin D1, c-Myc, and HIF-1a and amplified cellular proliferation after cisplatin injury, whereas forced expression of a constitutively active mutant of GSK3b abrogated the effects of lithium. Mechanistically, GSK3b colocalized and physically interacted with cyclin D1, c-Myc, and HIF-1a in tubular cells. In silico analysis revealed that cyclin D1, c-Myc, and HIF-1a harbor putative GSK3b consensus phosphorylation motifs, implying GSK3b-directed phosphorylation and subsequent degradation of these molecules. Notably, cotreatment with lithium enhanced the proapoptotic effects of cisplatin in cultured colon cancer cells. Collectively, our findings suggest that pharmacologic targeting of GSK3b by lithium may be a novel therapeutic strategy to improve renal salvage after AKI.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Delayed Administration of a Single Dose of Lithium Promotes Recovery from AKI

Bao

Wang

et al. 2014

Journal of the American Society of Nephrology

View full text Add to dashboard Cite

show abstract

“…Co-administration of lithium and carbamazepine has been suggested in patients with suspected carbamazepine-induced neutropenia, and in those who have bipolar disorder unresponsive to lithium alone (Brewerton, 1986;Vieweg et al, 1986).…”

Section: Other Psychoactive Drugs and Leucopeniamentioning

confidence: 99%

Haematological toxicity of drugs used in psychiatry

Flanagan

Dunk

2007

Hum. Psychopharmacol. Clin. Exp.

193

154

View full text Add to dashboard Cite

“…It has been shown to have a positive effect on tissue repair and regeneration in both the central nervous system and hematopoietic system. It causes leukocytosis ( 33 ) and increased gray matter in humans ( 34 ). In a study by Bao et al in mouse models of cisplatin as well as ischemia/reperfusion-induced AKI, there was a reduction in serum creatinine (SCr) in lithium treated mice as compared to controls.…”

Section: Introductionmentioning

confidence: 99%

Rationale and Design of Assessing the Effectiveness of Short-Term Low-Dose Lithium Therapy in Averting Cardiac Surgery-Associated Acute Kidney Injury: A Randomized, Double Blinded, Placebo Controlled Pilot Trial

et al. 2021

View full text Add to dashboard Cite

Background: Burgeoning pre-clinical evidence suggests that therapeutic targeting of glycogen synthase kinase 3β (GSK3β), a convergence point of multiple cellular protective signaling pathways, confers a beneficial effect on acute kidney injury (AKI) in experimental models. However, it remains unknown if GSK3β inhibition likewise mitigates AKI in humans. Cardiac surgery associated acute kidney injury (CSA-AKI) poses a significant challenge for clinicians and currently the only treatment available is general supportive measures. Lithium, an FDA approved mood stabilizer, is the best-known GSK3β inhibitor and has been safely used for over half a century as the first line regimen to treat bipolar affective disorders. This study attempts to examine the effectiveness of short term low dose lithium on CSA-AKI in human patients.Methods/Design: This is a single center, prospective, randomized, double blinded, placebo controlled pilot study on patients undergoing cardiac surgery with cardiopulmonary bypass. Patients will be randomized to receive a small dose of lithium or placebo treatment for three consecutive days. Renal function will be measured via creatinine as well as novel AKI biomarkers. The primary outcome is incidence of AKI according to Acute Kidney Injury Network (AKIN) criteria, and secondary outcomes include receipt of new dialysis, days on dialysis, days on mechanical ventilation, infections within 1 month of surgery, and death within 90 days of surgery.Discussion: As a standard selective inhibitor of GSK3β, lithium has been shown to exert a beneficial effect on tissue repair and regeneration upon acute injury in multiple organ systems, including the central nervous system and hematopoietic system. In experimental AKI, lithium at small doses is able to ameliorate AKI and promote kidney repair. Successful completion of this study will help to assess the effectiveness of lithium in CSA-AKI and could potentially pave the way for large-scale randomized trials to thoroughly evaluate the efficacy of this novel regimen for preventing AKI after cardiac surgery.Trial Registration: This study was registered prospectively on the 17th February 2017 at ClinicalTrials.gov (NCT03056248, https://clinicaltrials.gov/ct2/show/NCT03056248?term=NCT03056248&draw=2&rank=1).

show abstract

Increase in white blood cell count and serum sodium level following the addition of lithium to carbamazephine treatment among three chronically psychotic male patients with disturbed affective states

Cited by 11 publications

References 12 publications

Delayed Administration of a Single Dose of Lithium Promotes Recovery from AKI

Delayed Administration of a Single Dose of Lithium Promotes Recovery from AKI

Haematological toxicity of drugs used in psychiatry

Rationale and Design of Assessing the Effectiveness of Short-Term Low-Dose Lithium Therapy in Averting Cardiac Surgery-Associated Acute Kidney Injury: A Randomized, Double Blinded, Placebo Controlled Pilot Trial

Contact Info

Product

Resources

About